Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
July 03 2024 - 5:00AM
Planegg/Martinsried, July 3,
2024. Medigene AG (Medigene or the “Company”, FSE: MDG1,
Prime Standard), an immuno-oncology platform company focusing on
the discovery and development of T cell immunotherapies for solid
tumors, announces today that the Company has been issued a patent
by the Chinese Patent Office protecting its T cell receptor (TCR)
targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1)
and LAGE 1a (L Antigen Family Member-1a), both being
well-recognized and validated cancer-testis antigens, expressed in
multiple tumor types.
“We are delighted to receive the patent grant of
our NY-ESO-1 / LAGE1a-targeted TCR in China. This TCR, together
with the PD1-41BB costimulatory switch protein, serves as the main
component of our lead TCR-T program MDG1015, for the treatment of
gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and
synovial sarcoma, for which we remain on track for a US IND
submission in the 3rd quarter of this year,“ said Selwyn Ho, CEO at
Medigene AG. “ Importantly, this adds to similar patents that were
also granted in the United States, Europe, Japan, South Korea,
Taiwan and Australia and further expands the opportunity to use our
optimal affinity 3S (sensitive, specific and safe) TCRs
internationally, across multiple therapeutic modalities, including
TCR-T therapies, TCR-guided T cell engagers and TCR natural killer
cell therapies.”
Medigene continually extends and strengthens its
patent portfolio with new technologies and expands existing patents
into additional jurisdictions. The Company maintains over 20
different patent families worldwide covering applications
protecting Medigene’s 3S TCRs as well as its exclusive E2E Platform
technologies.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology
platform company dedicated to developing differentiated T cell
therapies for treatment of solid tumors. Its End-to-End Platform is
built on multiple proprietary and exclusive technologies that
enable the Company to generate optimal T cell receptors against
both cancer testis antigens and neoantigens, armor and enhance
these T cell receptor engineered (TCR) -T cells to create
best-in-class, differentiated TCR-T therapies, and optimize the
drug product composition for safety, efficacy and durability. The
End-to-End Platform provides product candidates for both its own
therapeutics pipeline and partnering. Medigene’s lead TCR-T program
MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4
2024. For more information, please visit https://medigene.com/
About Medigene’s MDG1015
Program
MDG1015 is a first-in-class, 3rd generation T
cell receptor engineered T cell (TCR-T) therapy targeting NY-ESO-1
/ LAGE-1a, a well-recognized and validated cancer testis antigen,
which is expressed in multiple tumor types. MDG1015 contains our
optimal affinity 3S (sensitive, specific and safe) NY-ESO-1
/LAGE-1a TCR combined with our proprietary PD1-41BB costimulatory
switch protein that blocks the PD1/PD-L1 inhibitory axis while
simultaneously activating the T cell through the well described
-41BB pathway further enhancing the activity and persistence of the
TCR-T cell in the hostile tumor microenvironment (TME). MDG1015 is
currently undergoing IND/CTA enabling studies with IND approval
expected in Q3 2024 and CTA approval in Q4 2024.
This press release contains forward-looking
statements representing the opinion of Medigene as of the date of
this release. The actual results achieved by Medigene may differ
significantly from the forward-looking statements made herein.
Medigene is not bound to update any of these forward-looking
statements. Medigene® is a registered trademark of Medigene AG.
This trademark may be owned or licensed in select locations
only.
Medigene AG
Pamela Keck Phone: +49 89 2000 3333 01 E-mail:
investor@medigene.com
In case you no longer wish to receive any
information about Medigene, please inform us by e-mail
(investor@medigene.com). We will then delete your address from our
distribution list.